Key Takeaways:

• Kimba raised $5.4 million in seed funding led by Selva Ventures.
• Kimba is introducing a clinically validated, AI-powered approach to improving sleep through adaptive scent therapy.
• Clinically proven and validated, the platform was developed alongside leading sleep and neuroscience researchers.

The clinically validated sleep technology company launched with $6.5 million in total funding to date to pioneer a new category of adaptive scent-based sleep improvement.

WHO: Founded by Ben Fuxbruner, a former special forces commander, after a near-death injury led to PTSD and chronic insomnia, the company was built from a personal need to solve one of the most persistent challenges in modern health: sleep. Developed alongside leading sleep and neuroscience researchers, Kimba sits at the intersection of consumer health and sleep science and is designed to actively improve sleep rather than simply track it. Kimba continuously monitors biometric signals throughout the night and delivers precisely timed scent cues through the olfactory pathway, the only sensory channel capable of reaching the brain during sleep without waking the user. The contactless system delivers personalized scent interventions designed to support deeper, more restorative rest without drugs or disruption. Kimba aims to reach 10,000 subscribers in its first year.

WHY: The funding will support Kimba’s commercial launch and accelerate the company’s efforts to redefine the sleep technology category by moving beyond passive tracking toward active, personalized sleep improvement.

IN THEIR OWN WORDS: “Kimba was built on a simple but powerful idea that sleep shouldn’t just be measured, it should be...